Advances in MicroRNA Therapeutics: From Preclinical to Clinical Studies
Human Gene Therapy · 2024-09 · 35 (17-18) · 628-648
DOI: 10.1089/hum.2024.113 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Human Gene Therapy, online erschienen am 13.09.2024. Verfasst von Simona Brillante und 2 weiteren Autor:innen. Beteiligte Einrichtung: Telethon Institute of Genetics and Medicine (TIGEM), Pozzuoli, Italy. Hauptthemen laut MEDLINE: MicroRNAs, Genetic Therapy. Die Arbeit wurde bisher 122-mal zitiert (Crossref) und nennt 163 Literaturangaben.
Abstract (Originalsprache)
MicroRNAs (miRNAs) are crucial regulators of gene expression involved in various pathophysiological processes. Their ability to modulate multiple pathways simultaneously and their involvement in numerous diseases make miRNAs attractive tools and targets in therapeutic development. Significant efforts have been made to advance miRNA research in the preclinical stage, attracting considerable investment from biopharmaceutical companies. Consequently, an increasing number of miRNA-based therapies have entered clinical trials for both diagnostic and therapeutic applications across a wide range of diseases. While individual miRNAs can regulate a broad array of mRNA targets, this also complicates the management of adverse effects seen in clinical trials. Several candidates have been discontinued due to toxicity concerns, underscoring the need for comprehensive risk assessments of miRNA therapeutics. Despite no miRNA-based strategies have yet received approval from regulatory agencies, prominent progress in the miRNA modulation approaches and in the nano-delivery systems have been made in the last decade, leading to the development of novel safe and well-tolerated miRNA drug candidates. In this review, we present recent advances in the development of miRNA therapeutics currently in preclinical or clinical stages for treating both rare genetic disorders and multifactorial common conditions. We also address the challenges related to the safety and targeted delivery of miRNA therapies, as well as the identification of the most effective therapeutic candidates in preclinical and clinical trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Telethon Institute of Genetics and Medicine (TIGEM), Pozzuoli, Italy.
- Institute for Genetic and Biomedical Research (IRGB), National Research Council (CNR), Milan, Italy.
ORCID-Profile: Alessia Indrieri
Zitieren
APA
Brillante, S., Volpe, M., & Indrieri, A. (2024). Advances in MicroRNA Therapeutics: From Preclinical to Clinical Studies. Human Gene Therapy, 35(17-18), 628-648. https://doi.org/10.1089/hum.2024.113
Vancouver
Brillante S, Volpe M, Indrieri A. Advances in MicroRNA Therapeutics: From Preclinical to Clinical Studies. Human Gene Therapy. 2024;35(17-18):628-648. doi:10.1089/hum.2024.113
BibTeX
@article{Brillante2024,
author = {Brillante, Simona and Volpe, Mariagrazia and Indrieri, Alessia},
title = {Advances in MicroRNA Therapeutics: From Preclinical to Clinical Studies},
journal = {Human Gene Therapy},
year = {2024},
volume = {35},
number = {17-18},
pages = {628--648},
doi = {10.1089/hum.2024.113}
}
EUVIMED